NZ738909A - Protease-resistant lipidated glp-1 analogs - Google Patents
Protease-resistant lipidated glp-1 analogsInfo
- Publication number
- NZ738909A NZ738909A NZ738909A NZ73890916A NZ738909A NZ 738909 A NZ738909 A NZ 738909A NZ 738909 A NZ738909 A NZ 738909A NZ 73890916 A NZ73890916 A NZ 73890916A NZ 738909 A NZ738909 A NZ 738909A
- Authority
- NZ
- New Zealand
- Prior art keywords
- peptides
- protease
- resistant
- mef
- amino acid
- Prior art date
Links
- 108091005804 Peptidases Proteins 0.000 title abstract 5
- 239000004365 Protease Substances 0.000 title abstract 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title abstract 5
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 7
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 7
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 150000002632 lipids Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000013016 Hypoglycemia Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 230000003914 insulin secretion Effects 0.000 abstract 1
- 230000029226 lipidation Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562173631P | 2015-06-10 | 2015-06-10 | |
| US201662343390P | 2016-05-31 | 2016-05-31 | |
| PCT/EP2016/063206 WO2016198544A1 (en) | 2015-06-10 | 2016-06-09 | Protease-resistant lipidated glp-1 analogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ738909A true NZ738909A (en) | 2019-08-30 |
Family
ID=56235790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ738909A NZ738909A (en) | 2015-06-10 | 2016-06-09 | Protease-resistant lipidated glp-1 analogs |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US10414811B2 (enExample) |
| EP (2) | EP3865504A1 (enExample) |
| JP (1) | JP6811190B2 (enExample) |
| KR (1) | KR20180016441A (enExample) |
| CN (1) | CN108271373B (enExample) |
| AU (2) | AU2016277449B2 (enExample) |
| CA (1) | CA2988841C (enExample) |
| CL (1) | CL2017003144A1 (enExample) |
| CO (1) | CO2017012675A2 (enExample) |
| CR (1) | CR20170559A (enExample) |
| DO (1) | DOP2017000287A (enExample) |
| EA (1) | EA036415B1 (enExample) |
| ES (1) | ES2849950T3 (enExample) |
| IL (1) | IL255978B (enExample) |
| MX (1) | MX389407B (enExample) |
| MY (1) | MY185816A (enExample) |
| NI (1) | NI201700156A (enExample) |
| NZ (1) | NZ738909A (enExample) |
| PE (1) | PE20180659A1 (enExample) |
| PH (1) | PH12017502259A1 (enExample) |
| SG (1) | SG10201911837SA (enExample) |
| SV (1) | SV2017005585A (enExample) |
| TN (1) | TN2017000519A1 (enExample) |
| TW (1) | TWI726889B (enExample) |
| WO (1) | WO2016198544A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017277594A1 (en) * | 2016-06-09 | 2019-02-07 | Medimmune Limited | Protease-resistant mono-lipidated peptides |
| AU2018360382A1 (en) * | 2017-10-31 | 2020-06-18 | Medimmune Limited | Oral delivery of GLP-1 peptide analogs |
| WO2019193576A1 (en) | 2018-04-05 | 2019-10-10 | Sun Pharmaceutical Industries Limited | Novel glp-1 analogues |
| CN116710462A (zh) | 2021-01-20 | 2023-09-05 | 维京治疗公司 | 用于治疗代谢病症和肝病的组合物和方法 |
| CA3231953A1 (en) | 2021-09-15 | 2023-03-23 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| TW202346323A (zh) * | 2022-02-07 | 2023-12-01 | 英商梅迪繆思有限公司 | 具有改善的生物穩定性的ｇｌｐ—１及升糖素雙重激動肽 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
| WO2004022004A2 (en) | 2002-09-06 | 2004-03-18 | Bayer Pharmaceuticals Corporation | Modified glp-1 receptor agonists and their pharmacological methods of use |
| CN101010339B (zh) * | 2004-07-02 | 2011-11-09 | 布里斯托尔-迈尔斯斯奎布公司 | 人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途 |
| AU2006287562B2 (en) * | 2005-09-08 | 2012-05-10 | Trustees Of Tufts College | Stabilized GLP-1 analogs |
| EP1854455B1 (en) * | 2006-05-10 | 2009-10-07 | Biocompatibles UK Limited | Spherical microcapsules comprising GLP-1 peptides, their production and use |
| EP2021014A1 (en) | 2006-05-26 | 2009-02-11 | Brystol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
| US20090318353A1 (en) | 2006-08-25 | 2009-12-24 | Novo Nordisk A/S | Acylated Exendin-4 Compounds |
| US8563521B2 (en) | 2007-06-21 | 2013-10-22 | Technische Universitat Munchen | Biological active proteins having increased in vivo and/or in vitro stability |
| ATE554098T1 (de) | 2007-12-11 | 2012-05-15 | Cadila Healthcare Ltd | Peptidomimetica mit glucagon-antagonistischen und glp-1-agonistischen aktivitäten |
| KR101740066B1 (ko) * | 2008-12-05 | 2017-05-25 | 글락소 그룹 리미티드 | 프로테아제 저항성 폴리펩티드를 선택하는 방법 |
| CA2765026A1 (en) | 2009-06-16 | 2010-12-23 | Indiana University Research And Technology Corporation | Gip receptor-active glucagon compounds |
| WO2011048614A2 (en) | 2009-10-22 | 2011-04-28 | Cadila Healthcare Limited | Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist |
| EP2569000B1 (en) | 2010-05-13 | 2017-09-27 | Indiana University Research and Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
| US20130143800A1 (en) | 2011-11-07 | 2013-06-06 | Research Development Foundation | Combination therapies to treat diabetes |
| AR092873A1 (es) * | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| EP3459598A1 (en) | 2012-12-06 | 2019-03-27 | Stealth Peptides International, Inc. | Combinations of peptide therapeutics and methods for using same |
| AU2014230472A1 (en) * | 2013-03-14 | 2015-10-01 | Medimmune Limited | Pegylated glucagon and GLP-1 co-agonists for the treatment of obesity |
| BR112016013157A2 (pt) | 2013-12-13 | 2017-09-26 | Medimmune Ltd | peptídeos resistentes à protease |
-
2016
- 2016-06-08 TW TW105118294A patent/TWI726889B/zh not_active IP Right Cessation
- 2016-06-09 AU AU2016277449A patent/AU2016277449B2/en not_active Ceased
- 2016-06-09 TN TNP/2017/000519A patent/TN2017000519A1/en unknown
- 2016-06-09 US US15/579,774 patent/US10414811B2/en active Active
- 2016-06-09 SG SG10201911837SA patent/SG10201911837SA/en unknown
- 2016-06-09 ES ES16732248T patent/ES2849950T3/es active Active
- 2016-06-09 EP EP20202888.2A patent/EP3865504A1/en not_active Withdrawn
- 2016-06-09 EP EP16732248.6A patent/EP3307769B1/en active Active
- 2016-06-09 WO PCT/EP2016/063206 patent/WO2016198544A1/en not_active Ceased
- 2016-06-09 CN CN201680033320.4A patent/CN108271373B/zh active Active
- 2016-06-09 EA EA201792640A patent/EA036415B1/ru not_active IP Right Cessation
- 2016-06-09 NZ NZ738909A patent/NZ738909A/en not_active IP Right Cessation
- 2016-06-09 CR CR20170559A patent/CR20170559A/es unknown
- 2016-06-09 CA CA2988841A patent/CA2988841C/en active Active
- 2016-06-09 JP JP2017563292A patent/JP6811190B2/ja active Active
- 2016-06-09 KR KR1020177037653A patent/KR20180016441A/ko not_active Ceased
- 2016-06-09 MX MX2017015482A patent/MX389407B/es unknown
- 2016-06-09 MY MYPI2017704708A patent/MY185816A/en unknown
- 2016-06-09 PE PE2017002540A patent/PE20180659A1/es unknown
-
2017
- 2017-11-28 IL IL255978A patent/IL255978B/en active IP Right Grant
- 2017-12-07 CL CL2017003144A patent/CL2017003144A1/es unknown
- 2017-12-07 DO DO2017000287A patent/DOP2017000287A/es unknown
- 2017-12-08 SV SV2017005585A patent/SV2017005585A/es unknown
- 2017-12-11 PH PH12017502259A patent/PH12017502259A1/en unknown
- 2017-12-11 NI NI201700156A patent/NI201700156A/es unknown
- 2017-12-11 CO CONC2017/0012675A patent/CO2017012675A2/es unknown
-
2019
- 2019-07-25 US US16/521,662 patent/US20200079833A1/en not_active Abandoned
- 2019-09-13 AU AU2019229424A patent/AU2019229424A1/en not_active Abandoned
-
2021
- 2021-02-08 US US17/169,833 patent/US20210221866A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ738909A (en) | Protease-resistant lipidated glp-1 analogs | |
| CY1125302T1 (el) | Συναγωνιστες γλυκαγονης και glp-1 για την αγωγη της παχυσαρκιας | |
| MX367348B (es) | Derivados de exendina-4 como agonistas selectivos del receptor de glucagon. | |
| MX336412B (es) | Nuevos analogos de glucagon. | |
| ECSP17084280A (es) | Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1) | |
| EA201990071A1 (ru) | Композиция пептидной вакцины | |
| PE20141727A1 (es) | Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas | |
| MY158627A (en) | Halogen-stabilized insulin | |
| IN2014KN02830A (enExample) | ||
| NZ721015A (en) | Mutant fragments of ospa and methods and uses relating thereto | |
| EA201791617A1 (ru) | Аналоги амилина | |
| MX2016007407A (es) | Peptidos resistentes a proteasa. | |
| NZ717035A (en) | Cortistatin analogues for the treatment of inflammatory and/or immune diseases | |
| PH12018502465A1 (en) | Mic-1 compounds and use thereof | |
| NZ703597A (en) | Mutant fragments of ospa and methods and uses relating thereto | |
| MX366906B (es) | Purificacion de iduronato-2-sulfatasa. | |
| CY1113726T1 (el) | Χρηση της πασιρεοτιδης για την αντιμετωπιση της ενδογενους υπερινσουλιναιμικης υπογλυκαιμιας | |
| MX353301B (es) | Composiciones tripeptidicas y metodos para tratamiento de diabetes. | |
| MX2018014966A (es) | Peptidos monolipidados resistentes a proteasas. | |
| MX357071B (es) | Medicamentos que comprenden apolipoproteína a-iv no glicosilada para el tratamiento de diabetes. | |
| NZ729514A (en) | Therapeutic multi-peptides t specific immune therapy for treatment of brain metastasis | |
| AU2010353685A8 (en) | Novel glucagon like peptide analogs, composition, and method of use | |
| PH12018501319A1 (en) | Insulinotropic peptide derivative with modified n-terminal charge | |
| PE20141549A1 (es) | VARIANTES DE CRIg MADURAS POR AFINIDAD | |
| EA201690966A1 (ru) | Новое соединение для лечения тяжелой гипогликемии |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUN 2021 BY CPA GLOBAL Effective date: 20200424 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JUN 2022 BY CPA GLOBAL Effective date: 20210422 |
|
| LAPS | Patent lapsed |